Treatment with Tyvaso (inhaled treprostinil) can improve lung function in people with pulmonary hypertension associated with interstitial lung disease (PH-ILD), new data from a completed Phase 2/3 clinical trial show. These data were presented at CHEST 2020, the annual meeting of the American College of…

Use of Bellerophon Therapeutics’s INOpulse device led to clinically meaningful improvements in people with pulmonary hypertension associated with interstitial lung disease (PH-ILD), according to initial data from an ongoing clinical study. PH-ILD is associated with constriction or narrowing of pulmonary arteries, which supply the lungs with…

Bellerophon reached its enrollment goal for the second group of patients in its ongoing Phase 2/3 trial evaluating different doses of INOpulse therapy for pulmonary hypertension associated with interstitial lung disease (PH-ILD), a illness for which no treatments exist. PH-ILD patients in group (or…

Low diffusing capacity of the lung for carbon monoxide (DLCO) is a key indicator of mortality in group 3 pulmonary hypertension (PH), according to a study. The finding suggests a potential tool to asses patient risk based on DLCO outcomes. The study, “Survival in pulmonary hypertension due to chronic…

A type of extracorporeal membrane oxygenation (ECMO), a life support technique used to oxygenate the blood, was seen to significantly improve survival in end-stage pulmonary hypertension (PH) and interstitial lung disease (ILD) patients awaiting lung transplants, a retrospective study suggests. Researchers found that when performed in a venoarterial,…

Bardoxolone methyl, Reata Pharmaceuticals’ treatment candidate for pulmonary hypertension (PH), improves exercise capacity and has a safe profile in patients with PH associated with interstitial lung disease (ILD), according to top-line results from a Phase 2 clinical trial. ILD is a group of several lung…

Bellerophon Therapeutics is advancing the clinical trials program of its inhaled INOpulse nitric oxide therapy for pulmonary hypertension (PH) associated with several lung diseases. The company is developing INOpulse for patients with pulmonary arterial hypertension (PAH), PH associated with chronic obstructive pulmonary disease (COPD), and PH linked to interstitial lung…

Scleroderma patients with newly diagnosed pulmonary arterial hypertension (PAH) have significantly higher healthcare costs than those without PAH, a Colorado study shows. The researchers said scleroderma patients with interstitial lung disease (ILD) also face higher costs. Both lung conditions are associated with poorer scleroderma patient survival, demonstrating the  need for…

Development work on INOpulse as a treatment for pulmonary hypertension is advancing in all three patient groups, Bellerophon Therapeutics announced when sharing its third quarter financial results. Bellerophon is developing INOpulse — inhaled nitric oxide delivered with the help of a portable device — for patients with pulmonary arterial hypertension…

Several factors may help predict the development of pulmonary arterial hypertension (PAH) in patients with systemic sclerosis (SSc), like older age and, for women, the drop in estrogen brought on by menopause, researchers report. Given that PAH is one of the main causes of mortality among SSc patients, their study raises…

Results showing the safety of Esbriet (pirfenidone) in treating interstitial lung disease due to systemic sclerosis were recently presented at the European League Against Rheumatism Annual European Congress of Rheumatology. The U.S. Food and Drug Administration approved Esbriet (pirfenidone), which is currently marketed by Roche, as a…